DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Cost-effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomized controled trial.

Author(s): Fautrel B, Benhamou M, Breban M, Roy C, Lenoir C, Trape G, Baleydier A, Ravaud P, Dougados M

Affiliation(s): Pierre et Marie Curie - Paris VI University, France.

Publication date & source: 2009-09-09, Ann Rheum Dis., [Epub ahead of print]

OBJECTIVE: To determine the incremental cost-effectiveness ratios (ICERs) of 2 therapeutic regimens of infliximab for ankylosing spondylitis (AS). METHODS: 230 patients with active AS who were participating in a randomized controlled trial comparing 2 infliximab infusion modalities - every 6 weeks (Q6) and on demand (DEM) - were included in an economic evaluation within the trial. Data were collected by phone every 3 months for 1 year. Direct and indirect costs were calculated from a payer perspective. Health-related quality of life was assessed with a general health rating scale. ICERs were calculated for one 20% improvement (ASAS20), for one partial remission and for one quality-adjusted life year (QALY) gained. RESULTS: The Q6 regimen was significantly more efficacious than the DEM regimen but also more costly (22,388 euro vs 17,596 euro; p<0.0001), because it required significantly more infliximab infusions per patient (8.4 vs 6.2). The ICERs of the Q6 to DEM regimen were 15,841 euro for one ASAS20 response, 23,296 euro for one partial remission and 50,760 euro for one QALY gained. CONCLUSION: The administration of infliximab every 6 weeks is cost-effective as compared with a DEM regimen; however, the ICER is close to the acceptability threshold of 50,000 euro for one QALY gained.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017